Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Cancer Immunol Immunother

Search In Journal Title:

Abbravation: Cancer Immunology, Immunotherapy

Search In Journal Abbravation:

Publisher

Springer Berlin Heidelberg

Search In Publisher:

DOI

10.1016/0043-1354(76)90144-5

Search In DOI:

ISSN

1432-0851

Search In ISSN:
Search In Title Of Papers:

Toward harmonized phenotyping of human myeloidder

Authors: Susanna Mandruzzato Sven Brandau Cedrik M Britten Vincenzo Bronte Vera Damuzzo Cécile Gouttefangeas Dominik Maurer Christian Ottensmeier Sjoerd H van der Burg Marij J P Welters Steffen Walter
Publish Date: 2016/01/04
Volume: 65, Issue: 2, Pages: 161-169
PDF Link

Abstract

There is an increasing interest for monitoring circulating myeloidderived suppressor cells MDSCs in cancer patients but there are also divergences in their phenotypic definition To overcome this obstacle the Cancer Immunoguiding Program under the umbrella of the Association of Cancer Immunotherapy is coordinating a proficiency panel program that aims at harmonizing MDSC phenotyping After a consultation period a twostage approach was designed to harmonize MDSC phenotype In the first step an international consortium of 23 laboratories immunophenotyped 10 putative MDSC subsets on pretested peripheral blood mononuclear cells of healthy donors to assess the level of concordance and define robust marker combinations for the identification of circulating MDSCs At this stage no mandatory requirements to standardize reagents or protocols were introduced Data analysis revealed a small intralaboratory but very high interlaboratory variance for all MDSC subsets especially for the granulocytic subsets In particular the use of a deadcell marker altered significantly the reported percentage of granulocytic MDSCs confirming that these cells are especially sensitive to cryopreservation and/or thawing Importantly the gating strategy was heterogeneous and associated with high intercenter variance Overall our results document the high variability in MDSC phenotyping in the multicenter setting if no harmonization/standardization measures are applied Although the observed variability depended on a number of identified parameters the main parameter associated with variation was the gating strategy Based on these findings we propose further efforts to harmonize marker combinations and gating parameters to identify strategies for a robust enumeration of MDSC subsets


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy
  2. Second International Symposium on Cancer Biology (ISCB), November 14–16, 2011, at the National Institute of Immunology, New Delhi, India
  3. Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients
  4. Saccharomyces cerevisiae , the Baker’s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice
  5. Higher numbers of T-bet + intratumoral lymphoid cells correlate with better survival in gastric cancer
  6. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E 2 results in high interleukin-12 production and cell migration
  7. Increase in CD14 + HLA-DR −/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
  8. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells
  9. Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma
  10. Epigenetic regulation of immune escape genes in cancer
  11. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis
  12. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses
  13. Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle
  14. −509C>T polymorphism in the TGF-β1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection
  15. Bridging the innate and adaptive immune responses against cancer: 95th AACR meeting 2004
  16. Heterogeneity of CD8 + tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies
  17. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma
  18. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
  19. Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells
  20. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms
  21. H 2 O 2 production within tumor microenvironment inversely correlated with infiltration of CD56 dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction
  22. Lenalidomide enhances anti-myeloma cellular immunity
  23. Epidemiology: allergy history, IgE, and cancer
  24. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
  25. Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
  26. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors
  27. Chordoma and chondrosarcoma gene profile: implications for immunotherapy
  28. Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma
  29. Extracellular adenosine metabolism in immune cells in melanoma
  30. Collective action of hematopoietic cell subsets mediates anti-IL10R1 and CpG tumor immunity
  31. Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
  32. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies
  33. Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function
  34. Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis

Search Result: